JP2000500662A5 - - Google Patents

Download PDF

Info

Publication number
JP2000500662A5
JP2000500662A5 JP1998508568A JP50856898A JP2000500662A5 JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5 JP 1998508568 A JP1998508568 A JP 1998508568A JP 50856898 A JP50856898 A JP 50856898A JP 2000500662 A5 JP2000500662 A5 JP 2000500662A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998508568A
Other languages
English (en)
Other versions
JP2000500662A (ja
JP4070815B2 (ja
Filing date
Publication date
Priority claimed from FR9609584A external-priority patent/FR2751879B1/fr
Application filed filed Critical
Publication of JP2000500662A publication Critical patent/JP2000500662A/ja
Publication of JP2000500662A5 publication Critical patent/JP2000500662A5/ja
Application granted granted Critical
Publication of JP4070815B2 publication Critical patent/JP4070815B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
Figure 2000500662
JP50856898A 1996-07-30 1997-07-29 パピローマウイルス腫瘍および感染を治療するための医薬組成物 Expired - Fee Related JP4070815B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/09584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007092639A Division JP4198735B2 (ja) 1996-07-30 2007-03-30 パピローマウイルス腫瘍および感染を治療するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2000500662A JP2000500662A (ja) 2000-01-25
JP2000500662A5 true JP2000500662A5 (ja) 2004-11-18
JP4070815B2 JP4070815B2 (ja) 2008-04-02

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50856898A Expired - Fee Related JP4070815B2 (ja) 1996-07-30 1997-07-29 パピローマウイルス腫瘍および感染を治療するための医薬組成物
JP2007092639A Expired - Fee Related JP4198735B2 (ja) 1996-07-30 2007-03-30 パピローマウイルス腫瘍および感染を治療するための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007092639A Expired - Fee Related JP4198735B2 (ja) 1996-07-30 2007-03-30 パピローマウイルス腫瘍および感染を治療するための医薬組成物

Country Status (12)

Country Link
EP (2) EP0862634B2 (ja)
JP (2) JP4070815B2 (ja)
AT (2) ATE265535T1 (ja)
AU (1) AU736720B2 (ja)
CA (1) CA2234263C (ja)
DE (2) DE69706825T3 (ja)
DK (2) DK0862634T4 (ja)
ES (2) ES2163795T5 (ja)
FR (1) FR2751879B1 (ja)
HK (1) HK1043809B (ja)
PT (2) PT862634E (ja)
WO (1) WO1998004705A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1089758A1 (fr) * 1998-06-26 2001-04-11 Aventis Pasteur Immunisation a ciblage mucosal
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
CA2749192A1 (en) 2009-01-20 2010-07-29 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
HUE026194T2 (en) 2009-03-24 2016-05-30 Transgene Sa Biomarker for checking patients
CN102395883B (zh) 2009-04-17 2015-12-02 特朗斯吉有限公司 用于监控患者的生物标志物
RU2560976C2 (ru) 2009-05-12 2015-08-20 Трансген Са Способ продуцирования и очистки ортопоксвируса
SG176619A1 (en) 2009-07-10 2012-01-30 Transgene Sa Biomarker for selecting patients and related methods
SG178090A1 (en) 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX2017007178A (es) 2014-12-01 2017-08-28 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
BR112022017438A2 (pt) 2020-03-12 2022-10-18 Bavarian Nordic As Composições que melhoram a estabilidade do poxvírus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
PT97073A (pt) 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK0595935T3 (da) * 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Similar Documents

Publication Publication Date Title
JP2001517383A5 (ja)
JP2000501599A5 (ja)
JP2000501018A5 (ja)
JP2000500076A5 (ja)
JP2000506991A5 (ja)
JP2000501324A5 (ja)
JP2000517258A5 (ja)
JP2000500055A5 (ja)
JP2000500026A5 (ja)
JP2000502472A5 (ja)
JP2000501338A5 (ja)
JP2000500874A5 (ja)
JP2000502485A5 (ja)
JP2000502570A5 (ja)
JP2000500912A5 (ja)
JP2000502568A5 (ja)
JP2001501991A5 (ja)
JP2000504734A5 (ja)
JP2000500857A5 (ja)
JP2000502714A5 (ja)
JP2001503287A5 (ja)
JP2000501229A5 (ja)
JP2000500318A5 (ja)
JP2000502479A5 (ja)
JP2001524931A5 (ja)